All In Biotech

Drug Trial Radar · NCT05411081

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Mar 24, 2023

Primary completion

Jul 1, 2027

Study completion Jul 1, 2027

Sponsor

Sponsor type
NIH
First posted
Jun 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of tumor cells. Combination therapy with atezolizumab and cabozantinib may shrink the tumor and allow a longer survival time in patients with metastatic renal cell carcinoma.

Conditions

  • Metastatic Papillary Renal Cell Carcinoma
  • Stage IV Renal Cell Cancer AJCC v8

Interventions

  • AtezolizumabBiological

    Given IV

  • Biospecimen CollectionProcedure

    Undergo collection of blood and urine samples

  • Bone ScanProcedure

    Undergo bone scans

  • Cabozantinib S-malateDrug

    Given PO

  • Computed TomographyProcedure

    Undergo CT scans

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survivalTime frame: From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 5 years

Locations

198 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Epic Care-Dublin

    Dublin, California

  • Epic Care Partners in Cancer Care

    Emeryville, California

  • Kaiser Permanente-Fontana

    Fontana, California

  • Kaiser Permanente South Bay

    Harbor City, California

  • Kaiser Permanente-Irvine

    Irvine, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • Kaiser Permanente West Los Angeles

    Los Angeles, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • Kaiser Permanente-Ontario

    Ontario, California

  • Kaiser Permanente - Panorama City

    Panorama City, California

  • Kaiser Permanente-Riverside

    Riverside, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Kaiser Permanente-San Diego Zion

    San Diego, California

  • Kaiser Permanente-San Marcos

    San Marcos, California

  • Epic Care Cyberknife Center

    Walnut Creek, California

  • Kaiser Permanente-Woodland Hills

    Woodland Hills, California

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Saint Alphonsus Cancer Care Center-Boise

    Boise, Idaho

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho

  • Saint Alphonsus Cancer Care Center-Caldwell

    Caldwell, Idaho

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho

  • Saint Luke's Cancer Institute - Twin Falls

    Twin Falls, Idaho

  • Illinois CancerCare-Bloomington

    Bloomington, Illinois

  • Illinois CancerCare-Canton

    Canton, Illinois

  • Illinois CancerCare-Carthage

    Carthage, Illinois

  • Northwestern University

    Chicago, Illinois

  • Carle at The Riverfront

    Danville, Illinois

Showing 40 of 198 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.